These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29491018)

  • 1. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
    Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
    J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between the BD Onclarity and Roche cobas assays for detection of HPV DNA in a Chinese population.
    Wang Y; Li T; Yin J; Liu Y; Li Z; Liu Y; Chen T; Chen S; Dai Y; Cui J; Liu B; Feng X; Zhang S; Chen W
    J Med Virol; 2022 Dec; 94(12):6037-6046. PubMed ID: 35978268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
    Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
    J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.
    Li T; Wu Z; Jiang M; Zhao Y; Yu L; Qin Y; Liu B; Cui J; Li L; Pan Q; Zhang X; Liu D; Chen F; Qiao Y; Chen W
    Gynecol Oncol; 2020 Apr; 157(1):202-208. PubMed ID: 31964506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
    Yu S; Kwon MJ; Lee EH; Park H; Woo HY
    J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens.
    Wright TC; Stoler MH; Agreda PM; Beitman GH; Gutierrez EC; Harris JM; Koch KR; Kuebler M; LaViers WD; Legendre BL; Leitch SV; Maus CE; McMillian RA; Nussbaumer WA; Palmer ML; Porter MJ; Richart GA; Schwab RJ; Vaughan LM
    Am J Clin Pathol; 2014 Jul; 142(1):43-50. PubMed ID: 24926084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.
    Schiffman M; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Apple R; Aldrich C; Erlich HA; Tam T; Befano B; Burk RD; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1304-10. PubMed ID: 26088703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VALGENT: A protocol for clinical validation of human papillomavirus assays.
    Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
    J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
    BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
    Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.
    Pesic A; Krings A; Hempel M; Preyer R; Chatzistamatiou K; Agorastos T; Kaufmann AM
    Virol J; 2019 Jul; 16(1):92. PubMed ID: 31337408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
    Gustavsson I; Aarnio R; Myrnäs M; Hedlund-Lindberg J; Taku O; Meiring T; Wikström I; Enroth S; Williamson AL; Olovsson M; Gyllensten U
    Virol J; 2019 Aug; 16(1):107. PubMed ID: 31438976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.